Next Article in Journal
Growth Factors Responsible from the Cancer Progress: Role of Natural Products
Previous Article in Journal
New Images. Imagination in the Process of Aesthetic Practice—The Process of Collage
Article Menu

Article Versions

Export Article

Open AccessAbstract
Proceedings 2017, 1(10), 980; doi:10.3390/proceedings1100980

Can Curcumin be Employed to Promote the Integration of Oncology and Natural Products?

1
Department of Medical Oncology, Medicana International Istanbul Hospital, Istanbul 34520, Turkey
2
Department of Medical Oncology, KTO Karatay University, Konya 42020, Turkey
3
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Bezmialem Vakif University,Istanbul 34093, Turkey
Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November 2017.
*
Author to whom correspondence should be addressed.
Published: 13 November 2017
Download PDF [137 KB, uploaded 13 November 2017]

Abstract

Nuclear Factor-Kappa B (NF-kB) is a key inflammatory transcription factor expressed frequently in tumors which, has an important role in proliferation, apoptosis, inflammatory and immune response. Several recent preclinical and clinical studies have shown that significant NF-kB expression is associated with chemoradiation resistance and poor outcome in several human cancers. It has been shown that curcumin inhibits NF-kB activation pathway at a step before inhibitor kappa B alfa (IKBα) phosphorylation. Preclinical in vivo and in vitro trials that combine curcumin with tyrosine kinase inhibitors (TKIs) have shown that this combination shows better results than each treatment alone. Retrospectively evaluated seventeen NF-kB overexpressed cancer patients were treated with i.v. and oral bioavailable formulation of curcumin and appropriate TKIs. TKIs decision was made according to genetic profiling (FoundationOne®). Toxicities and response was evaluated according to RECIST and common toxicities criteria. All patients are stage IV and heavily pretreated. Our longest experience comes from adenoid cystic carcinoma and he has treated for 72 months by oral curcumin and 8 months by i.v curcumin. Disease control rate was 89.3% (15/17) and no any grade III-IV toxicities was observed related to curcumin. Curcumin is multitargeted molecule with pleotrophic nature. Curcumin inhibits NF-κB and related proteins which promotes effectiveness of TKIs. And might be considered as long as we have to use chemotherapy, radiotherapy and TKI.
Keywords: Curcumin; NF-kB inhibition; tyrosine kinase inhibitors Curcumin; NF-kB inhibition; tyrosine kinase inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Demiray, M.; Bahadori, F. Can Curcumin be Employed to Promote the Integration of Oncology and Natural Products? Proceedings 2017, 1, 980.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proceedings EISSN 2504-3900 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top